Anzeige
Mehr »
Login
Sonntag, 03.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ0R | ISIN: US75513E1010 | Ticker-Symbol: 5UR
Tradegate
01.11.24
20:52 Uhr
109,90 Euro
-0,04
-0,04 %
1-Jahres-Chart
RTX CORPORATION Chart 1 Jahr
5-Tage-Chart
RTX CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
109,00109,8802.11.
109,60110,2601.11.
GlobeNewswire (Europe)
239 Leser
Artikel bewerten:
(1)

Ducommun Incorporated Announces Award of Major Defense Orders for Raytheon Radar Systems

SANTA ANA, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) ("Ducommun" or the "Company"), a global supplier of innovative electronic and structural solutions for the aerospace & defense industry, is proud to announce two major awards totaling over $50M in revenue for the Raytheon SPY-6 family of radar systems. These two awards represent a $25M follow on order for one circuit card assembly already in production, along with another $25M order for one circuit card assembly that will be brand new production for DCO. All cards will be produced at Ducommun's world-class engineering and manufacturing performance center for circuit cards assemblies in Tulsa, Oklahoma.

"We are thrilled to have earned the trust of Raytheon on this most critical Navy radar system as we continue to build out this part of our defense business by supporting off-loading from our strategic defense customers. This is a very important initiative for us and one I have been talking about with shareholders on our quarterly earning calls. We are also now moving more and more into radar systems for defense, which complements our already significant circuit card assemblies' franchise for missiles, such as MIR and the family of Standard Missiles" said Stephen G. Oswald, chairman, president, and chief executive officer. "Raytheon has treated us as a true partner, given us many opportunities and we are committed to continue delivering value for them and their customers."

With the addition of these two new major awards, the Company's backlog continues to break all-time high records at over $1B, which benefits shareholders for years to come. Ducommun currently provides Raytheon with electronics, circuit card assemblies, harness cable assemblies, and structural products on both legacy and emerging programs.

About Ducommun Incorporated
Ducommun Incorporated delivers value-added innovative manufacturing solutions to customers in the aerospace, defense, and industrial markets. Founded in 1849, the company specializes in two core areas - Electronic Systems and Structural Systems - to produce complex products and components for commercial aircraft platforms, mission-critical military and space programs, and sophisticated industrial applications. For more information, visit Ducommun.com.

About RTX Corporation
RTX is the world's largest aerospace and defense company. With more than 185,000 global employees, it pushes the limits of technology and science to redefine how it connects and protects our world. Through industry-leading businesses - Collins Aerospace, Pratt & Whitney, and Raytheon - it is advancing aviation, engineering integrated defense systems for operational success, and developing next-generation technology solutions and manufacturing to help global customers address their most critical challenges.

Forward-Looking Statements
This press release includes "forward looking statements" within the meaning of the of the federal securities laws relating to Ducommun Incorporated, including statements relating to Ducommun's expectations pertaining to opportunities under agreements with its key customers, its backlog and its benefit to shareholders, and similar expressions that concern Ducommun's intentions or beliefs about future occurrences, expectations, or results. Forward looking statements are subject to risks, uncertainties and other factors that may change over time and may cause actual results to differ materially from those that are expected. It is very difficult to predict the effect of known factors, and Ducommun cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties, and other factors, including those factors disclosed under "Risk Factors" in our reports filed with the SEC, including the Company's Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, Current Reports on Form 8-K and its other filings with the SEC. The forward-looking statements included in this press release are made only as of the date of this press release, and Ducommun does not undertake any obligation to (and expressly disclaims any such obligation to) update the forward looking statements to reflect subsequent events or circumstances.

MEDIA CONTACTS:
Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665
SMookerji@ducommun.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.